The receptor for advanced glycation end products (RAGE) and the lung.
Affiliation
School of Pharmacy and Pharmaceutical Sciences, Trinity College Dublin, Dublin 2, Ireland.Issue Date
2010
Metadata
Show full item recordCitation
The receptor for advanced glycation end products (RAGE) and the lung. 2010, 2010:917108 J. Biomed. Biotechnol.Journal
Journal of biomedicine & biotechnologyDOI
10.1155/2010/917108PubMed ID
20145712Abstract
The receptor for advanced glycation end products (RAGE) is a member of the immunoglobulin superfamily of cell surface molecules. As a pattern-recognition receptor capable of binding a diverse range of ligands, it is typically expressed at low levels under normal physiological conditions in the majority of tissues. In contrast, the lung exhibits high basal level expression of RAGE localised primarily in alveolar type I (ATI) cells, suggesting a potentially important role for the receptor in maintaining lung homeostasis. Indeed, disruption of RAGE levels has been implicated in the pathogenesis of a variety of pulmonary disorders including cancer and fibrosis. Furthermore, its soluble isoforms, sRAGE, which act as decoy receptors, have been shown to be a useful marker of ATI cell injury. Whilst RAGE undoubtedly plays an important role in the biology of the lung, it remains unclear as to the exact nature of this contribution under both physiological and pathological conditions.Language
enISSN
1110-7251ae974a485f413a2113503eed53cd6c53
10.1155/2010/917108